Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Effects of SGLT2 inhibitors on atherosclerosis: lessons from cardiovascular clinical outcomes in type 2 diabetic patients and basic researches
J Xu, T Hirai, D Koya, M Kitada - Journal of Clinical Medicine, 2021 - mdpi.com
Atherosclerosis-caused cardiovascular diseases (CVD) are the leading cause of mortality in
type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter 2 (SGLT2) inhibitors are …
type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter 2 (SGLT2) inhibitors are …
SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews
Introduction Sodium glucose co-transporter 2 (SGLT2) inhibitors have been reported to
benefit liver functions in patients with type 2 diabetes (T2D) with non-alcoholic fatty liver …
benefit liver functions in patients with type 2 diabetes (T2D) with non-alcoholic fatty liver …
Use of SGLT2 inhibitors vs GLP-1 RAs and anemia in patients with diabetes and CKD
Importance Sodium-glucose cotransporter 2 (SGLT2) inhibitors are associated with lower
anemia risk, based on findings from post hoc analyses of the CREDENCE and DAPA-CKD …
anemia risk, based on findings from post hoc analyses of the CREDENCE and DAPA-CKD …
The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 …
AWC Ling, CC Chan, SW Chen, YW Kao… - Cardiovascular …, 2020 - Springer
Background Sodium glucose cotransporter 2 inhibitor (SGLT2i) reduces the risk of hard
cardiovascular endpoints in type 2 diabetes mellitus (T2DM) patients with/without …
cardiovascular endpoints in type 2 diabetes mellitus (T2DM) patients with/without …
Population diversity of cardiovascular outcome trials and real-world patients with diabetes in a Chinese tertiary hospital
YL Zhou, YG Zhang, R Zhang, YL Zhou… - Chinese Medical …, 2021 - journals.lww.com
Background: Recent cardiovascular outcome trials (CVOTs) changed the therapeutic
strategy of guidelines for type 2 diabetes. We compared the characteristics of patients from …
strategy of guidelines for type 2 diabetes. We compared the characteristics of patients from …
Positive predictive value of ICD-10-cm codes for myocarditis in claims data: a multi-institutional study in Taiwan
LY Wu, SC Shao, SC Liao - Clinical Epidemiology, 2023 - Taylor & Francis
Purpose The validity of the diagnosis codes to identify myocarditis cases in healthcare
databases research remains unclear, and this study aimed to determine the coding accuracy …
databases research remains unclear, and this study aimed to determine the coding accuracy …
New-onset atrial fibrillation in patients with type 2 diabetes treated with novel glucose-lowering therapies
FC Hsiao, KC Yen, TF Chao, SW Chen… - The Journal of …, 2022 - academic.oup.com
Context Whether sodium-glucose cotransporter 2 inhibitors (SGLT2is) are associated with
lower risk of new-onset atrial fibrillation (AF) compared with glucagon-like peptide-1 receptor …
lower risk of new-onset atrial fibrillation (AF) compared with glucagon-like peptide-1 receptor …
A real-world study on SGLT2 inhibitors and diabetic kidney disease progression
Background Randomized controlled trials have demonstrated the benefits of sodium–
glucose cotransporter 2 inhibitors (SGLT2is) in people with type 2 diabetes mellitus (T2DM) …
glucose cotransporter 2 inhibitors (SGLT2is) in people with type 2 diabetes mellitus (T2DM) …
Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis
Background Cardiovascular outcome trials of sodium-glucose co-transporter-2 inhibitors
(SGLT2i CVOTs) found the agents to be associated with clinical benefits in terms of …
(SGLT2i CVOTs) found the agents to be associated with clinical benefits in terms of …
Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE‐TIMI 58 study
Aims To evaluate comprehensively the safety of dapagliflozin in patients with type 2
diabetes (T2DM), with emphasis placed on potential safety concerns related to the sodium …
diabetes (T2DM), with emphasis placed on potential safety concerns related to the sodium …